FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2053193025> ?p ?o ?g. }

• W2053193025 endingPage "2014" @default.
• W2053193025 startingPage "2014" @default.
• W2053193025 abstract "Abstract Background: Two randomized phase 2 studies investigated the efficacy of cetuximab (C), a mAb directed against EGFR, in metastatic breast cancer (MBC) patients (pts). Trial 1 (T1) compared the response rates in triple negative breast cancer (TNBC) pts on C vs. C plus carboplatin (Cb), and, in Trial 2 (T2), both TNBC and ER+/HER2- pt subsets were assessed for response to irinotecan (I) plus Cb vs. C plus ICb. In T2, TNBC pts showed an improved objective response rate with C treatment, while ER+/HER2- pts did not. Formalin-fixed paraffin-embedded (FFPE) primary breast cancer tissues were available from pts on both trials for retrospective analyses of potential predictive biomarkers of C treatment.Material and Methods: In T1 and T2, 64 and 68 pts, respectively, had tissue for qRT-PCR analyses of genes important for breast cancer subtyping (PAM50) and EGFR pathway-related genes. PAM50 analysis showed that 76 of the 132 pts on the 2 trials had basal-like breast cancer (BBC). In T1, 43 of the 64 (67%) TNBC pts had BBC, 3 were HER2-enriched, 5 were luminal A and 13 were normal-like breast cancer. In this trial, 10 of 64 pts (16%) had progression-free survival (PFS) duration ≥6 mo (long remitters [LRs]) with 4 pts having PFS ≥12 mo; 6 of the 10 LRs had BBC. In T2, 22 of 68 pts were LRs (32%) (11 of 22 received C) and 9 pts had PFS ≥12 mo (5 received C). 11 of the 37 BBC pts in T2 had PFS ≥6 mo (5 received C) and 4 of 11 had PFS ≥12 mo (2 received C). The following EGFR pathway-related markers were also assessed by qRT-PCR: EGFR, KRAS, PTEN, alpha basic crystallin (CRYAB) gene expression, and K-Ras amplification (average expression by qPCR of 7 genes in KRAS amplicon). Expression of these markers was compared in the pts who had PFS of &lt;6 mo versus ≥6mo, with or without C treatment, and in the BBC vs. non-BBC subtypes.Results: In preliminary analyses, in T1 (all C-treated pts), higher levels of EGFR expression trended with PFS ≥6 mo in both BBC pts (p=.09) and non-BBC pts (p=.06). In T2, a trend towards benefit with C with high EGFR levels was seen in non-BBC but not BBC pts. In both trials, resistance to treatment in general was associated with low PTEN or high CRYAB levels. BBC and non-BBC pts with low PTEN or high CRYAB did not benefit from C. Interestingly, in T2, non-BBC benefit from C was associated with significantly higher PTEN levels (p=.04). Lack of KRAS amplification predicted for benefit from C in BBC (but not in non-BBC) in T1 (p=.09) and in T2 benefit with C was seen in BBC that lacked KRAS amplification. KRAS gene expression alone did not appear to distinguish the MBC pts who were LRs vs. not, regardless of C therapy. Additional analyses correlating benefit from C therapy with EGFR and PTEN expression by IHC, and with KRAS and PIK3CA mutation status on T2 will be available in addition to updated analyses of the above markers.Conclusion: Approximately 15% of the MBC pts with FFPE tissue available for molecular analyses had prolonged benefit with C in 2 randomized phase 2 trials. Preliminary results from our analyses suggest that benefit from C in MBC may be correlated with lower expression of CRYAB, with higher expression of PTEN, and in BBC, with lack of KRAS amplification. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 2014." @default.
• W2053193025 created "2016-06-24" @default.
• W2053193025 creator A5003084219 @default.
• W2053193025 creator A5007846490 @default.
• W2053193025 creator A5022854192 @default.
• W2053193025 creator A5023605651 @default.
• W2053193025 creator A5023840204 @default.
• W2053193025 creator A5024059719 @default.
• W2053193025 creator A5028916394 @default.
• W2053193025 creator A5040177206 @default.
• W2053193025 creator A5041912334 @default.
• W2053193025 creator A5050616688 @default.
• W2053193025 creator A5052268581 @default.
• W2053193025 creator A5056077449 @default.
• W2053193025 creator A5062969331 @default.
• W2053193025 creator A5071738043 @default.
• W2053193025 creator A5081258470 @default.
• W2053193025 date "2009-12-01" @default.
• W2053193025 modified "2023-10-17" @default.
• W2053193025 title "Potential Predictive Markers of Benefit from Cetuximab in Metastatic Breast Cancer: An Analysis of Two Randomized Phase 2 Trials." @default.
• W2053193025 doi "https://doi.org/10.1158/0008-5472.sabcs-09-2014" @default.
• W2053193025 hasPublicationYear "2009" @default.
• W2053193025 type Work @default.
• W2053193025 sameAs 2053193025 @default.
• W2053193025 citedByCount "13" @default.
• W2053193025 countsByYear W20531930252014 @default.
• W2053193025 countsByYear W20531930252015 @default.
• W2053193025 countsByYear W20531930252016 @default.
• W2053193025 countsByYear W20531930252017 @default.
• W2053193025 crossrefType "journal-article" @default.
• W2053193025 hasAuthorship W2053193025A5003084219 @default.
• W2053193025 hasAuthorship W2053193025A5007846490 @default.
• W2053193025 hasAuthorship W2053193025A5022854192 @default.
• W2053193025 hasAuthorship W2053193025A5023605651 @default.
• W2053193025 hasAuthorship W2053193025A5023840204 @default.
• W2053193025 hasAuthorship W2053193025A5024059719 @default.
• W2053193025 hasAuthorship W2053193025A5028916394 @default.
• W2053193025 hasAuthorship W2053193025A5040177206 @default.
• W2053193025 hasAuthorship W2053193025A5041912334 @default.
• W2053193025 hasAuthorship W2053193025A5050616688 @default.
• W2053193025 hasAuthorship W2053193025A5052268581 @default.
• W2053193025 hasAuthorship W2053193025A5056077449 @default.
• W2053193025 hasAuthorship W2053193025A5062969331 @default.
• W2053193025 hasAuthorship W2053193025A5071738043 @default.
• W2053193025 hasAuthorship W2053193025A5081258470 @default.
• W2053193025 hasConcept C121608353 @default.
• W2053193025 hasConcept C126322002 @default.
• W2053193025 hasConcept C143998085 @default.
• W2053193025 hasConcept C2775930923 @default.
• W2053193025 hasConcept C2776694085 @default.
• W2053193025 hasConcept C2778239845 @default.
• W2053193025 hasConcept C2779998722 @default.
• W2053193025 hasConcept C2780110267 @default.
• W2053193025 hasConcept C2781451048 @default.
• W2053193025 hasConcept C526805850 @default.
• W2053193025 hasConcept C530470458 @default.
• W2053193025 hasConcept C71924100 @default.
• W2053193025 hasConceptScore W2053193025C121608353 @default.
• W2053193025 hasConceptScore W2053193025C126322002 @default.
• W2053193025 hasConceptScore W2053193025C143998085 @default.
• W2053193025 hasConceptScore W2053193025C2775930923 @default.
• W2053193025 hasConceptScore W2053193025C2776694085 @default.
• W2053193025 hasConceptScore W2053193025C2778239845 @default.
• W2053193025 hasConceptScore W2053193025C2779998722 @default.
• W2053193025 hasConceptScore W2053193025C2780110267 @default.
• W2053193025 hasConceptScore W2053193025C2781451048 @default.
• W2053193025 hasConceptScore W2053193025C526805850 @default.
• W2053193025 hasConceptScore W2053193025C530470458 @default.
• W2053193025 hasConceptScore W2053193025C71924100 @default.
• W2053193025 hasIssue "24_Supplement" @default.
• W2053193025 hasLocation W20531930251 @default.
• W2053193025 hasOpenAccess W2053193025 @default.
• W2053193025 hasPrimaryLocation W20531930251 @default.
• W2053193025 hasRelatedWork W1791486331 @default.
• W2053193025 hasRelatedWork W2046474315 @default.
• W2053193025 hasRelatedWork W2053193025 @default.
• W2053193025 hasRelatedWork W2080991642 @default.
• W2053193025 hasRelatedWork W2162097880 @default.
• W2053193025 hasRelatedWork W2261491225 @default.
• W2053193025 hasRelatedWork W2317787856 @default.
• W2053193025 hasRelatedWork W3186887399 @default.
• W2053193025 hasRelatedWork W2506107499 @default.
• W2053193025 hasRelatedWork W2983167088 @default.
• W2053193025 hasVolume "69" @default.
• W2053193025 isParatext "false" @default.
• W2053193025 isRetracted "false" @default.
• W2053193025 magId "2053193025" @default.
• W2053193025 workType "article" @default.